Danaher estimates Q4 revenue up mid-single digits YoY; core revenue and FY EPS at high-end of guidance

DANAHER CORP /DE/

2025-FY EPS reported $5.05 revenue$24,568,000,000

Estimated Q4 2025 revenue up mid-single-digit percent YoY; non-GAAP core revenue growth toward high-end of low-single-digit guidance.
Full-year 2025 adjusted diluted EPS expected toward high-end of $7.70–$7.80 guidance range.
CEO cites continued strength in Bioprocessing and better-than-expected Life Sciences and Diagnostics revenue in Q4.
Danaher will report full Q4 and FY2025 earnings on January 28, 2026.
Presentation at J.P. Morgan Healthcare Conference on January 13; live webcast on Danaher's website.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.